Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.30 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1406090 | 0.71 | KEAP1 (0.50) | HRH4KIF11KEAP1NFE2L2MEN1 | |
| SCHEMBL24451732 | 0.67 | DHFR (0.44) | DAODHFRSLC2A1KIF11KEAP1 | |
| SCHEMBL10321624 | 0.66 | HRH4 (0.43) | HRH4DAOKIF11KEAP1NFE2L2 | |
| SCHEMBL22374561 | 0.66 | HRH4 (0.43) | HRH4KIF11KEAP1NFE2L2MEN1 | |
| SCHEMBL3100612 | 0.64 | HRH4 (0.60) | HRH4DAOMEN1KMT2A | |
| SCHEMBL3432805 | 0.64 | DAO (0.67) | HRH4DAO | |
| SCHEMBL23424577 | 0.60 | CES2 (0.38) | NFE2L2MEN1KMT2A | |
| SCHEMBL16380899 | 0.60 | DAO (0.49) | HRH4DAODHFRSLC2A1KIF11 | |
| SCHEMBL10067384 | 0.59 | KIF11 (0.49) | KIF11KEAP1NFE2L2MEN1KMT2A | |
| SCHEMBL5622542 | 0.59 | KDM4E (0.56) | HRH4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303489-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303489-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | FUS, TFEB, CLN6 | HRH4 4847/4885DAO 4321/4885DHFR 4782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.